Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Reed's, Inc. reported its second quarter 2026 financial results with net sales decreasing to $7.5 million from $9.5 million a year ago, driven by lower volumes from national customers. However, the company demonstrated operational improvements with gross profit increasing to $1.8 million and gross margin rising to 24% from 8%. Operating expenses an…
Ferrari trades at a premium, but recent Q2 strength, a raised 2026 guide, aggressive buybacks and the most complete product lineup in decades justify owning the stock. This trade idea lays out an actionable long with entry, stop and target for a long-term holding (180 trading days), explains the fundamental drivers and balances the bull case with c…
Sanara MedTech Inc. reported a 9% increase in net revenue to $28.1 million for Q2 2026 compared to Q2 2025, with strong gross margins of 93%. The company announced an expected acquisition by MiMedx, aiming to create a leading regenerative medicine company. Despite a slight net loss due to increased SG&A and interest expenses, Adjusted EBITDA improv…
Cardiff Oncology announced positive Phase 2 clinical trial results for onvansertib combined with FOLFIRI/bevacizumab in first-line RAS-mutated metastatic colorectal cancer at ASCO 2026. Following a successful End-of-Phase 2 meeting with the FDA, the company plans to initiate a Phase 3 registrational trial in early 2027, contingent on securing addit…
Firefly Aerospace announced its second-quarter 2026 financial results with record revenue of $117.7 million, a 659% year-over-year increase. The company secured over six contracts in Q2, including a $144 million NASA Commercial Lunar Payload Services contract for a rapid Moon lander mission and a $75 million subcontract supporting NASA's MoonFall m…
Quantinuum and Oracle announced a multi-year collaboration to make Quantinuum’s Helios quantum computer available through Oracle Cloud Infrastructure’s quantum service. Financial terms and a deployment date were not disclosed. Helios will run on-site within OCI, integrate under existing governance frameworks, and be hosted in a U.S.-based Oracle AI…
SINTX Technologies provided a mid-year 2026 business update highlighting progress in commercializing its FDA-cleared SiNAPTIC Foot & Ankle Implant System, expansion of its distribution network, additional capital raises, and growth in its industrial ceramics segment. The company is moving from technology development to commercial execution, investi…
Seer, Inc., a proteomics technology company, announced its second quarter 2026 financial results, reporting $3.1 million in revenue, a 23% decline year-over-year, driven by macroeconomic challenges and elongated sales cycles. Despite the revenue decline, gross margin remained solid at 49%, operating expenses and net loss decreased compared to the p…
Mineralys Therapeutics announced its second quarter 2026 financial results, including a strengthened balance sheet following a $150 million public offering and a $100 million tranche drawn on a $500 million term loan. The company is on track for FDA's PDUFA target date of December 22, 2026, for lorundrostat, an aldosterone synthase inhibitor target…
H&R Block reported fiscal 2026 financial results showcasing a 5% revenue increase to $3.95 billion, a 21% rise in net income from continuing operations, and a 29% increase in earnings per share. The company returned $714 million to shareholders through dividends and share repurchases, raising its quarterly dividend by 10%. For fiscal 2027, it proje…
SELLAS Life Sciences reported its Q2 2026 financial results, highlighting progress in its lead cancer drug candidates GPS and SLS009, both targeting acute myeloid leukemia (AML). The Phase 3 REGAL trial for GPS is nearing the critical 80th event for final analysis, potentially leading to FDA Biologics License Application submission. The Phase 2 tri…
Mobile Infrastructure Corporation reported its second quarter 2026 financial results with same-location revenue growth of 5.6% year-over-year and contract parking volumes increasing approximately 12%. Despite a slight decrease in total revenue due to recent asset sales, same-location net operating income rose 12%. The company paid down $4.5 million…
Hour Loop, Inc., a U.S.-based online retailer, announced its second quarter 2026 financial results with net revenues increasing 25% year-over-year to $33.9 million. Despite higher revenues, net income slightly declined to $1.1 million from $1.2 million, reflecting margin pressures and increased costs. The company continues to invest in inventory an…
Firefly Aerospace has announced a two-year extension of its multi-launch agreement with Lockheed Martin to utilize the Alpha Block II rocket configuration for up to 25 launches through 2031. This upgrade enhances manufacturability, reliability, and responsiveness, allowing Firefly to meet high demand for dedicated launches in the 1,000 kg payload c…
High Roller Technologies reported its Q2 2026 financials, marked by a revenue decline due to strategic market exits and a focus on prediction markets. The company achieved significant regulatory milestones for its ROLR prediction platform, gaining approval as a member of the National Futures Association and planning a U.S. launch via Crypto.com der…
Inuvo, Inc. reported its Q2 2026 financial results, highlighting a 19% year-over-year growth in Audience Modeling revenue driven by new client wins and increased investment from existing customers. However, total net revenue declined 67% due to an 80% decrease in Legacy Search revenue. The company took strategic steps to reduce costs associated wit…
Factorial Energy Inc., a Nasdaq-listed company specializing in solid-state battery technology, announced its financial and business results for Q2 2026. The company highlighted its leadership in the development of scalable solid-state batteries for aerospace, energy storage, and mobility applications, supported by significant partnerships with majo…
Comscore has announced a comprehensive ROI Strategy aimed at transforming its business by realigning operations, optimizing organizational efficiency, and investing in future growth areas. The plan includes reducing annual costs by $20 to $25 million through restructuring and headcount reduction, simplifying operations, improving product developmen…
Nasdaq announced its end-of-month short interest data as of July 31, 2026. The report shows a slight decrease in the total shares sold short in both the Nasdaq Global Market and Nasdaq Capital Market compared to the prior reporting period. The days to cover metric has modestly increased, indicating a slight change in market shorting trends.
Insight Molecular Diagnostics (IMDX) announced a virtual key opinion leader event featuring prominent experts to discuss the GraftAssure platform, which utilizes digital PCR technology to enable rapid and reliable donor-derived cell-free DNA testing for transplanted organ health monitoring. The GraftAssureDx test kit is currently under FDA review t…
Mobia Medical, a medical device company specializing in stroke recovery technologies, reported a robust second quarter 2026 with $13.5 million revenue, up 102% year-over-year, and gross margin of 83.2%. The company completed its IPO, raising $134 million in net proceeds, strengthening its cash position to $177.1 million. It also announced publicati…
Anterix Inc. announced its fiscal 2027 first quarter results, highlighting $33.1 million of contracted proceeds outstanding, $15.7 million received from customers, and a gain of $10.7 million from exchanging narrowband for broadband licenses. The company maintains a strong balance sheet with $116 million in cash, no debt, and an authorized share re…
Absci Corporation announced positive interim Phase 1 data from its HEADLINE trial of ABS-201, an anti-prolactin receptor antibody targeting pattern hair loss and endometriosis. The company completed a $100 million underwritten offering with a $40 million strategic investment from Eli Lilly, bolstering cash reserves to $201.1 million, sufficient to …
BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) announced its Q2 2026 financial results and corporate progress, highlighting advancements in its pipeline targeting KRAS-mutant cancers, initiation of combination clinical trials, presentation of promising preclinical data, and a cash runway expected to fund operations into 2028.
MacroGenics announced that Gilead Sciences has exercised its option under their 2022 collaboration agreement to exclusively license a preclinical bispecific program targeting solid tumors. This action triggers a $10 million milestone payment to MacroGenics. The collaboration includes one clinical-stage and two preclinical bispecific programs, with …
